Literature DB >> 10833325

On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis.

R T Bartus1.   

Abstract

Life's Journey If life is indeed a journey, then poetry must be the map that reveals all its topographic possibilitiesellipsis while science is the compass that keeps us from getting lost. -R. T. Bartus, Simple Words for Complex Lives, (c) 1998 In the nearly 20 years since the cholinergic hypothesis was initially formulated, significant progress has been achieved. Initial palliative treatments for Alzheimer's disease (AD) have proven beneficial and have gained FDA approval, the use of animal models for studying AD and other neurodegenerative diseases has achieved wider acceptance, and important insight into the potential causes and pathogenic variables associated with various neurodegenerative diseases continues to increase. This paper reviews the current status of the cholinergic hypothesis in the context of continuing efforts to improve upon existing treatments for AD and explores the role that animal models might continue to play. Using the benefit of hindsight, particular emphasis is placed on an analysis of the approaches, strategies, and assumptions regarding animal models that proved useful in developing the initial treatments and those that did not. Additionally, contemporary issues of AD are discussed within the context of the cholinergic hypothesis, with particular attention given to how they may impact the further refinement of animal models, and the development of even more effective treatments. Finally, arguments are presented that, despite the deserved enthusiasm and optimism for identifying means of halting the pathogenesis of AD, a clear need for more effective palliative treatments will continue, long after successful pathogenic treatments are available. This review, therefore, focuses on issues and experiences intended to: (a) facilitate further development and use of animal models for AD and other neurodegenerative diseases, and (b) accelerate the identification of newer, even more effective treatments. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833325     DOI: 10.1006/exnr.2000.7397

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  191 in total

1.  Enantiomer effects of huperzine A on the aryl acylamidase activity of human cholinesterases.

Authors:  Sultan Darvesh; Ryan Walsh; Earl Martin
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

Review 2.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

3.  Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study.

Authors:  Raffaele Nardone; Pierpaolo De Blasi; Martin Seidl; Yvonne Höller; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski; Eugen Trinka
Journal:  J Neural Transm (Vienna)       Date:  2011-04-24       Impact factor: 3.575

4.  Impaired processes of working memory in the monkey model of Alzheimer's disease.

Authors:  K N Dudkin; I V Chueva; F N Makarov; T G Beach; A Roher
Journal:  Dokl Biol Sci       Date:  2002 Mar-Apr

5.  Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition.

Authors:  Patrizia De Sarno; Svetlana A Shestopal; Taj D King; Anna Zmijewska; Ling Song; Richard S Jope
Journal:  J Biol Chem       Date:  2003-01-21       Impact factor: 5.157

6.  Alterations of the sensory and cognitive components of operative memory in a monkey model of Alzheimer's disease.

Authors:  K N Dudkin; I V Chueva; F N Makarov; T G Beach; A E Roher
Journal:  Dokl Biol Sci       Date:  2003 Mar-Apr

7.  A computer-assisted cognitive test battery for aged monkeys.

Authors:  Jerry J Buccafusco; Alvin V Terry; Paul B Murdoch
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

8.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Authors:  Evan P Lebois; Thomas M Bridges; L Michelle Lewis; Eric S Dawson; Alexander S Kane; Zixiu Xiang; Satyawan B Jadhav; Huiyong Yin; J Phillip Kennedy; Jens Meiler; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

Review 9.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

10.  Ketamine impairs multiple cognitive domains in rhesus monkeys.

Authors:  Michael A Taffe; Sophia A Davis; Tannia Gutierrez; Lisa H Gold
Journal:  Drug Alcohol Depend       Date:  2002-10-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.